NBTX

Nanobiotix S.A. NASDAQ Listed Dec 11, 2020

Healthcare ·Biotechnology ·FR · nanobiotix.com

$42.61

Pre-mkt $50.52 +4.73%

Mkt Cap $2.1B

52w Low $3.26 95.5% of range 52w High $44.46

50d MA $32.43 200d MA $21.49

P/E (TTM) -70.2x

EV/EBITDA -81.5x

P/B —

Debt/Equity -1.1x

ROE —

P/FCF -27.7x

RSI (14) —

ATR (14) —

Beta 0.55

50d MA $32.43

200d MA $21.49

Avg Volume 55.4K

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

SIC Code

2834

CIK (SEC)

1760854

Phone

33 1 40 26 04 70

60 rue de Wattignies · Paris, I0 75012 · FR

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 31, 2026	AMC	0.30	-0.46	-250.7%	30.87	+6.6%	+10.4%	-8.9%	+5.5%	-8.0%	+2.2%	—
Sep 30, 2025	AMC	-0.25	-0.13	+45.9%	18.89	-0.2%	-0.8%	+6.1%	+3.2%	+11.1%	-7.9%	—
Apr 2, 2025	AMC	-0.62	-1.01	-63.5%	3.40	-2.6%	-0.6%	-3.3%	-3.1%	-4.7%	+5.0%	—
Nov 12, 2024	AMC	-0.51	-0.50	+2.5%	4.03	-2.0%	-3.0%	+3.6%	-3.0%	-3.3%	-0.5%	—
Apr 24, 2024	AMC	-0.83	-0.33	+60.4%	5.90	+0.2%	+0.2%	-2.9%	+1.2%	+0.5%	+2.7%	—
Nov 13, 2023	AMC	-0.59	-0.87	-47.6%	5.78	+5.4%	-1.0%	+2.2%	+2.7%	+1.9%	+0.1%	—
Mar 28, 2023	AMC	—	-0.95	—	3.60	-4.7%	-4.7%	+5.8%	-2.8%	+0.0%	+7.6%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 2	Guggenheim	Maintains	Buy → Buy	—	$34.07	$31.03	-8.9%	-8.9%	+5.5%	-8.0%	+2.2%	-0.7%
Feb 6	Guggenheim	Maintains	Buy → Buy	—	$21.03	$21.18	+0.7%	-0.9%	+13.0%	+12.1%	-8.7%	+1.5%
Apr 4	Guggenheim	Maintains	Buy → Buy	—	$3.38	$3.17	-6.2%	-3.3%	-3.1%	-4.7%	+5.0%	+0.3%
Jan 6	Evercore ISI	Maintains	Outperform → Outperform	—	$19.18	$18.49	-3.6%	+0.6%	-5.6%	+4.8%	-1.4%	-0.4%

Data updated apr 26, 2026 2:23pm · Source: massive.com